These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32546992)

  • 1. Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Yuda N; Tanaka M; Yamauchi K; Abe F; Kakiuchi I; Kiyosawa K; Miyasaka M; Sakane N; Nakamura M
    Clin Interv Aging; 2020; 15():743-754. PubMed ID: 32546992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety evaluation of high-dose intake of casein-derived peptide Met-Lys-Pro in healthy adults: A randomized, double-blind, placebo-controlled trial.
    Yuda N; Tanaka M; Tokushima M; Abe F
    Food Sci Nutr; 2021 Feb; 9(2):662-671. PubMed ID: 33598151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment.
    Steiner GZ; Bensoussan A; Liu J; Hohenberg MI; Chang DH
    Trials; 2018 Sep; 19(1):522. PubMed ID: 30253809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.
    Guekht AB; Moessler H; Novak PH; Gusev EI;
    J Stroke Cerebrovasc Dis; 2011; 20(4):310-8. PubMed ID: 20656516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid with or without vitamin B12 for cognition and dementia.
    Malouf M; Grimley EJ; Areosa SA
    Cochrane Database Syst Rev; 2003; (4):CD004514. PubMed ID: 14584018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Teprenone in Patients with Alzheimer's Disease.
    Yokoyama S; Yoshinaga T; Matsuzaki J; Suzuki H
    J Alzheimers Dis; 2019; 71(4):1187-1199. PubMed ID: 31498121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
    Sampson EL; Jenagaratnam L; McShane R
    Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4
    Xu Q; Zhang Y; Zhang X; Liu L; Zhou B; Mo R; Li Y; Li H; Li F; Tao Y; Liu Y; Xue C
    Clin Nutr; 2020 Jul; 39(7):2092-2105. PubMed ID: 31694759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
    Aronson S; Van Baelen B; Kavanagh S; Schwalen S
    Drugs Aging; 2009; 26(3):231-9. PubMed ID: 19358618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group.
    Le Bars PL; Katz MM; Berman N; Itil TM; Freedman AM; Schatzberg AF
    JAMA; 1997 Oct 22-29; 278(16):1327-32. PubMed ID: 9343463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
    Farina N; Llewellyn D; Isaac MGEKN; Tabet N
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002854. PubMed ID: 28418065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
    Lawlor B; Segurado R; Kennelly S; Olde Rikkert MGM; Howard R; Pasquier F; Börjesson-Hanson A; Tsolaki M; Lucca U; Molloy DW; Coen R; Riepe MW; Kálmán J; Kenny RA; Cregg F; O'Dwyer S; Walsh C; Adams J; Banzi R; Breuilh L; Daly L; Hendrix S; Aisen P; Gaynor S; Sheikhi A; Taekema DG; Verhey FR; Nemni R; Nobili F; Franceschi M; Frisoni G; Zanetti O; Konsta A; Anastasios O; Nenopoulou S; Tsolaki-Tagaraki F; Pakaski M; Dereeper O; de la Sayette V; Sénéchal O; Lavenu I; Devendeville A; Calais G; Crawford F; Mullan M;
    PLoS Med; 2018 Sep; 15(9):e1002660. PubMed ID: 30248105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
    Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
    N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).
    Veroff AE; Bodick NC; Offen WW; Sramek JJ; Cutler NR
    Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):304-12. PubMed ID: 9876958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
    Wilkinson D; Windfeld K; Colding-Jørgensen E
    Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.